1
|
Amini-Adle M, Arnault JP, Aubin F, Beneton N, Bens G, Brunet-Possenti F, Célerier P, Charles J, Crumbach L, Dalac S, Darras S, De Quatrebarbes J, Dinulescu M, Dutriaux C, Gaudy C, Gérard E, Giacchero D, Granel-Brocard F, Grange F, Jouary T, Kramkimel N, Lebbé C, Le Corre Y, Legoupil D, Lesage C, Lesimple T, Lorphelin JM, Mansard S, Martin L, Mary-Prey S, Maubec E, Meyer N, Mignard C, Montaudie H, Mortier L, Nardin C, Neidhardt Berard EM, Pagès Laurent C, Peuvrel L, Quereux G, Robert C, Saiag P, Saint-Jean M, Samimi M, Sassolas B, Scalbert C, Skowron F, Steff M, Stoebner PE, Trablesi S, Visseaux L, Zehou O, Boespflug A. The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns. Ann Dermatol Venereol 2024; 151:103243. [PMID: 38325268 DOI: 10.1016/j.annder.2023.103243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2023] [Revised: 04/06/2023] [Accepted: 09/05/2023] [Indexed: 02/09/2024]
Affiliation(s)
- M Amini-Adle
- Dermatology Department, Centre Léon Bérard, Lyon, France.
| | - J-P Arnault
- Dermatology Department, Centre Hospitalo-Universitaire, Amiens Picardie, France
| | - F Aubin
- Université de Bourgogne-Franche-Comté, Dermatology Department, Head of the Skin Cancer Unit, Centre Hospitalo-Universitaire de Besançon, Besançon, France; INSERM UMR RIGHT 1098, Besançon, France
| | - N Beneton
- Dermatology Department, Centre Hospitalier, Le Mans, France
| | - G Bens
- Dermatology Department, Centre Hospitalier, Orléans, France
| | - F Brunet-Possenti
- Dermatology Department, Centre Hospitalo-Universitaire Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - P Célerier
- Dermatology Department, Centre Hospitalier La Rochelle-Ré-Aunis, La Rochelle, France
| | - J Charles
- Dermatology Department, Centre Hospitalo-Universitaire, Grenoble, France
| | - L Crumbach
- Dermatology Department, Centre Léon Bérard, Lyon, France
| | - S Dalac
- Dermatology Department, Centre Hospitalo-Universitaire, Dijon, France
| | - S Darras
- Dermatology Department, Centre Hospitalier de Boulogne-sur-Mer, France
| | - J De Quatrebarbes
- Dermatology Department, Centre Hospitalier Annecy Genevois, Annecy, France
| | - M Dinulescu
- Dermatology Department, Centre Hospitalo-Universitaire, Rennes, France
| | - C Dutriaux
- Dermatology Department, Centre Hospitalo-Universitaire, Bordeaux, France
| | - C Gaudy
- Dermatology Department, Centre Hospitalo-Universitaire, Marseille, France
| | - E Gérard
- Dermatology Department, Centre Hospitalo-Universitaire, Bordeaux, France
| | | | - F Granel-Brocard
- Dermatology Department, Hôpitaux de Brabois Allée de Morvan, Vandoeuvre Les Nancy, France
| | - F Grange
- Dermatology Department, Centre Hospitalier, Valence, France
| | - T Jouary
- Dermatology Department, Hôpital François Mitterrand, Pau, France
| | - N Kramkimel
- Dermatology Department, Centre Hospitalo-Universitaire Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - C Lebbé
- Dermatology Department, Centre Hospitalo-Universitaire Saint Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Y Le Corre
- Dermatology Department, Centre Hospitalo-Universitaire Angers, France
| | - D Legoupil
- Dermatology Department, Centre Hospitalo-Universitaire Régional, Brest, France
| | - C Lesage
- Dermatology Department, Hôpital Saint Eloi, Montpellier, France
| | | | - J-M Lorphelin
- Dermatology Department, Centre Hospitalo-Universitaire, Caen, France
| | - S Mansard
- Dermatology Department, Centre Hospitalo-Universitaire, Clermont Ferrand, France
| | - L Martin
- Dermatology Department, Centre Hospitalo-Universitaire, Angers, France; Groupe Ethique de la Société Française de Dermatologie, France
| | - S Mary-Prey
- Centre Hospitalo-Universitaire Saint André, Bordeaux, France
| | - E Maubec
- Dermatology Department, Centre Hospitalo-Universitaire Avicenne, Assistance Publique-Hôpitaux de Paris, Bobigny, France
| | - N Meyer
- Institut Universitaire du Cancer et Centre Hospitalo-Universitaire, Toulouse, France
| | - C Mignard
- Dermatology Department, Centre Hospitalo-Universitaire, Rouen, France
| | - H Montaudie
- Dermatology Department, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice, France; INSERM U1065, Team 12, Centre Méditerranéen de Médecine Moléculaire, Université Nice Côte d'Azur, Nice, France
| | - L Mortier
- Dermatology Department, Centre Hospitalier Régional Universitaire, Lille, France
| | - C Nardin
- Université de Bourgogne-Franche-Comté et Centre Hospitalier Universitaire, Besançon, France; IINSERM UMR RIGHT 1098, Besançon, France
| | | | - C Pagès Laurent
- Institut Universitaire du Cancer et Centre Hospitalo-Universitaire, Toulouse, France
| | - L Peuvrel
- Medical Oncology Department, Institut de Cancérologie de l'Ouest, Saint Herblain, France
| | - Gaelle Quereux
- Dermatology Department, Centre Hospitalo-Universitaire, Nantes Université, Nantes, France; INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302, Nantes, France
| | - Caroline Robert
- Dermatology Department, Institut Gustave Roussy, Villejuif, France
| | - Philippe Saiag
- Dermatology Department, Centre Hospitalo-Universitaire Ambroise Paré, Assistance Publique-Hôpitaux de Paris, Boulogne Billancourt, France
| | - Mélanie Saint-Jean
- Medical Oncology Department, Institut de Cancérologie de l'Ouest, Saint Herblain, France
| | - M Samimi
- Dermatology Department, Centre Hospitalo-Universitaire, Tours, France
| | - B Sassolas
- Institute of Oncology & Hematology, Hôpital Morvan, Centre Hospitalier Régional Universitaire, Brest, France
| | - C Scalbert
- Dermatology Department, Centre Hospitalier Ouest Réunion, Saint Paul, Ile de la Réunion, France
| | - F Skowron
- Dermatology Department, Hôpitaux Drome Nord, Romans Sur Isère, France
| | - M Steff
- Dermatology Department, Centre Hospitalier Intercommunal Robert Ballanger, Aulnay sous-Bois, France
| | - P-E Stoebner
- Dermatology Department, Centre Hospitalo-Universitaire, Nîmes, France
| | - S Trablesi
- Dermatology Department, Centre Hospitalo-Universitaire, Grenoble, France
| | - L Visseaux
- Polyclinique Reims Bezannes, Bezannes, France
| | - O Zehou
- Dermatology Department, Centre Hospitalo-Universitaire Henri Mondor, Assistance Publique-Hôpitaux de Paris, Créteil, France
| | - A Boespflug
- Dermatology Department, Centre Hospitalier Henri Mondor, Villejuif, France
| |
Collapse
|
2
|
Khelef K, Maubec E, Jeudy G, Bonniaud B, Pham-Ledard A, Herms F, Aubin F, Beneton N, Dinulescu M, Jannic A, Duval-Modeste A, Archier E, Berthin C, Grange F, Arnault J, Heidelberger V, Moncourier M, Mansard S, Brunet-Possenti F, Triller R, Pracht M, Dumas M, Lauche O, Mortier L, Bedane C, Dalac Rat S. Duration of treatment with cemiplimab in advanced cutaneous squamous cell carcinoma in complete response: Real-life study. J Eur Acad Dermatol Venereol 2024; 38:e71-e73. [PMID: 37595320 DOI: 10.1111/jdv.19435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2023] [Accepted: 08/11/2023] [Indexed: 08/20/2023]
Affiliation(s)
- K Khelef
- Service de Dermatologie, Centre Hospitalier Universitaire (CHU), Dijon, France
| | - E Maubec
- Service de Dermatologie, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (APHP), Bobigny, France
- Campus de Bobigny-Université Sorbonne Paris Nord, Bobigny, France
- UMR 1124, Campus Saint Germain des Prés, Paris, France
| | - G Jeudy
- Service de Dermatologie, Centre Hospitalier Universitaire (CHU), Dijon, France
| | - B Bonniaud
- Service de Dermatologie, Centre Hospitalier Universitaire (CHU), Dijon, France
| | - A Pham-Ledard
- Service de Dermatologie, CHU de Bordeaux, Bordeaux, France
- Université de Bordeaux, Bordeaux, France
| | - F Herms
- Service de Dermatologie, Hôpital Saint-Louis, APHP, Paris, France
| | - F Aubin
- Service de Dermatologie, INSERM 1098, CHU de Besançon de Franche Comté, Besançon, France
- Université de Bourgogne-Franche-Comté, Besançon, France
| | - N Beneton
- Service de Dermatologie, CH du Mans, Le Mans, France
| | - M Dinulescu
- Service de Dermatologie, Hôpital Pontchaillou, Rennes, France
| | - A Jannic
- Service de Dermatologie, Hôpital Henri-Mondor, APHP, Créteil, France
| | - A Duval-Modeste
- Service de Dermatologie, Hôpital Charles-Nicolle, Rouen, France
| | - E Archier
- Service de Dermatologie, Hôpital Saint-Joseph, Marseille, France
| | - C Berthin
- Service de Dermatologie, CHU d'Angers, Angers, France
| | - F Grange
- Service de Dermatologie, CHU de Reims, Reims, France
| | - J Arnault
- Service de Dermatologie, CHU Amiens-Picardie, Amiens, France
| | - V Heidelberger
- Service de Dermatologie, CH Robert-Ballanger, Aulnay-sous-Bois, France
| | - M Moncourier
- Service de Dermatologie, CHU de Grenoble-Alpes, Grenoble, France
| | - S Mansard
- Service de Dermatologie, CHU de Clermont-Ferrand, Clermont-Ferrand, France
| | | | - R Triller
- Service de Dermatologie, Institut Franco-Britannique, Levallois-Perret, France
| | - M Pracht
- Groupe Hospitalier de St-Malo, Saint-Malo, France
| | - M Dumas
- Service de Dermatologie, CH René-Dubos, Pontoise, France
| | - O Lauche
- Clinique Clémentville, Montpellier, France
| | - L Mortier
- Service de Dermatologie, CHU de Lille, Lille, France
- INSERM U 1189, Université de Lille, Lille, France
| | - C Bedane
- Service de Dermatologie, Centre Hospitalier Universitaire (CHU), Dijon, France
| | - S Dalac Rat
- Service de Dermatologie, Centre Hospitalier Universitaire (CHU), Dijon, France
| |
Collapse
|
3
|
Dietrich E, Bara C, Chassain K, Scard C, Beneton N, Maillard H. Overview of dermatologic tele-expertise in areas of low physician density: A retrospective study at Le Mans general hospital. Ann Dermatol Venereol 2023:S0151-9638(23)00027-3. [PMID: 37270319 DOI: 10.1016/j.annder.2023.02.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2022] [Revised: 12/28/2022] [Accepted: 02/21/2023] [Indexed: 06/05/2023]
Abstract
BACKGROUND In areas of low physician density, especially as regards dermatologists in France, there is an increasing interest in tele-expertise. This is particularly the case in the Sarthe department, where the number of physicians continues to decline and access to care was further limited by the COVID 19 epidemic. STUDY DESIGN We retrospectively collected data from tele-expertise requests submitted to Le Mans General Hospital by general practitioners via a dedicated platform between May 6, 2019, and April 9, 2021. RESULTS Six hundred and forty three requests relating to 90 different diagnoses were recorded during this period. One hundred and thirty four patients (20% of requests) were invited to attend a face-to-face consultation within an average of 29 days. DISCUSSION Through the use of tele-expertise at Le Mans Genreal Hospital it was possible to introduce a means of tackling the problem of the lack of dermatologists in the Sarthe department. Rapid responses enabled the number of consultation requests to be reduced, leading to fewer population displacements in the context of the present pandemic. CONCLUSION These initial results are encouraging and confirm that tele-expertise seems a satisfactory option to optimize access to care for populations in areas of low physician density.
Collapse
Affiliation(s)
- E Dietrich
- Service de Dermatologie, Centre Hospitalier, Le Mans, France.
| | - C Bara
- Service de Dermatologie, Centre Hospitalier, Le Mans, France
| | - K Chassain
- Service de Dermatologie, Centre Hospitalier, Lorient, France
| | - C Scard
- Service de Dermatologie, Centre Hospitalier, Le Mans, France
| | - N Beneton
- Service de Dermatologie, Centre Hospitalier, Le Mans, France
| | - H Maillard
- Service de Dermatologie, Centre Hospitalier, Le Mans, France
| |
Collapse
|
4
|
Arlegui H, Mahé E, Richard MA, De Rycke Y, Viguier M, Beylot-Barry M, Dupuy A, Beneton N, Joly P, Jullien D, Bachelez H, Sbidian É, Chosidow O, Paul C, Tubach F. Impact of the first wave of the COVID-19 pandemic on the treatment of psoriasis with systemic therapies in France: Results from the PSOBIOTEQ cohort. Ann Dermatol Venereol 2023:S0151-9638(23)00009-1. [PMID: 36914553 PMCID: PMC9928748 DOI: 10.1016/j.annder.2023.01.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2022] [Revised: 11/18/2022] [Accepted: 01/31/2023] [Indexed: 02/17/2023]
Abstract
BACKGROUND The nature of the COVID-19 pandemic led to concerns among patients and physicians about the potential impact of immunosuppressive treatments for chronic diseases such as psoriasis on the risk of severe COVID-19. OBJECTIVES To describe treatment modifications and determine the incidence of COVID-19 infection among psoriasis patients during the first wave of the pandemic, and identify the factors associated with these events. METHODS Data from PSOBIOTEQ cohort relating to the first COVID-19 wave in France (March to June, 2020), as well as a patient-centred COVID-19 questionnaire, were used to evaluate the impact of lockdown on changes (discontinuations, delays or reductions) in systemic therapies, and to determine the incidence of COVID-19 cases among these patients. Logistic regression models were used to assess associated factors. RESULTS Among the 1751 respondents (89.3%), 282 patients (16.9%) changed their systemic treatment for psoriasis, with 46.0% of these changes being initiated by the patients themselves. Patients were more likely to experience psoriasis flare-ups during the first wave if they changed their treatment during this period (58.7% vs 14.4%; P < 0.0001). Changes to systemic therapies were less frequent among patients with cardiovascular diseases (P < 0.001), and those aged ≥ 65 years (P = 0.02). Overall, 45 patients (2.9%) reported having COVID-19, and eight (17.8%) required hospitalization. Risk factors for COVID-19 infection were close contact with a positive case (P < 0.001) and living in a region with a high incidence of COVID-19 (P < 0.001). Factors associated with a lower risk of COVID-19 were avoiding seeing a physician (P = 0.002), systematically wearing a mask during outings (P = 0.011) and being a current smoker (P = 0.046). CONCLUSIONS Discontinuation of systemic psoriasis treatments during the first COVID-19 wave (16.9%) - mainly decided by patients themselves (46.0%) - was associated with a higher incidence of disease flares (58.7% vs 14.4%). This observation and factors associated with a higher risk of COVID-19 highlight the need to maintain and adapt patient-physician communication during health crises according to patient profiles, with the aim of avoiding unnecessary treatment discontinuations and ensuring that patients are informed about the risk of infection and the importance of complying with hygiene rules.
Collapse
Affiliation(s)
- H Arlegui
- AP-HP, Hôpital Pitié-Salpêtrière, Centre de Pharmaco-épidémiologie (Cephépi), INSERM, CIC-1901, Paris, France
| | - E Mahé
- Service de Dermatologie, Hôpital Victor Dupouy, Argenteuil, France
| | - M-A Richard
- Service de Dermatologie, EA 3279: CEReSS - Health Service Research and Quality of Life Centre, Timone Hospital, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille University, Marseille, France
| | - Y De Rycke
- Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Département de Santé Publique, Centre de Pharmaco-épidémiologie (Cephépi), CIC-1901, 75013 Paris, France
| | - M Viguier
- Service de Dermatologie-Vénéréologie, Hôpital Robert Debré, Université Reims Champagne Ardenne, 51100 Reims, France
| | - M Beylot-Barry
- Service de Dermatologie, CHU de Bordeaux, Translational Research on Oncodermatology and Rare skin diseases, Bordeaux Institute of Oncology, UMR 1312 INSERM, Université Bordeaux, Bordeaux, France
| | - A Dupuy
- France Univ Rennes, CHU Rennes, 35000 Rennes, France
| | - N Beneton
- REPERES Pharmaco-Epidemiology and Health Services Research, University Rennes and French School of Public Health, Rennes, France
| | - P Joly
- Service de Dermatologie, Hôpital du Mans, Le Mans, France
| | - D Jullien
- Service de Dermatologie, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon F-69003; Lyon-1 University; INSERM U1111 - CIRI, Lyon F-69007, France
| | - H Bachelez
- Service de Dermatologie, Assistance Publique- Hôpitaux de Paris, Hôpital Saint-Louis, Université Paris Cité, Paris, France; INSERM UMR1163, Institut Imagine, Paris, France
| | - É Sbidian
- Service de Dermatologie, Assistance Publique- Hôpitaux de Paris, Hôpital Saint-Louis, Université Paris Cité, Paris, France; Hôpital Henri Mondor, Clinical Investigation Centre, Université Paris-Est Créteil (UPEC), Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE) - EA 7379, Créteil, France
| | - O Chosidow
- Service de Dermatologie, Assistance Publique- Hôpitaux de Paris, Hôpital Saint-Louis, Université Paris Cité, Paris, France; Groupe de recherche Dynamyc, EA7380, Faculté de Santé de Créteil, École nationale vétérinaire d'Alfort, USC ANSES, Université Paris-Est Créteil, Créteil, France
| | - C Paul
- Service de Dermatologie, Toulouse University Hospital (CHU), Paul Sabatier University, Toulouse, France
| | - F Tubach
- Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Département de Santé Publique, Centre de Pharmaco-épidémiologie (Cephépi), CIC-1901, 75013 Paris, France.
| | | |
Collapse
|
5
|
Robert J, Marchand A, Mazereeuw-Hautier J, Boccara O, Martin L, Chiaverini C, Beneton N, Vabres P, Balguerie X, Plantin P, Bessis D, Barbarot S, Dadban A, Droitcourt C, Samimi M, Morel B, Caille A, Maruani A, Leducq S. Quality of life of children with capillary malformations of the lower limbs: Evolution and associated factors. Data from the French national paediatric cohort, CONAPE. Ann Dermatol Venereol 2022; 149:271-275. [PMID: 35810006 DOI: 10.1016/j.annder.2022.03.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2021] [Revised: 02/16/2022] [Accepted: 03/30/2022] [Indexed: 01/19/2023]
Affiliation(s)
- J Robert
- University Hospital Center of Tours (CHRU), Department of Dermatology, Unit of Pediatric Dermatology, 37044 Tours Cedex 9, France; CHRU Tours, Reference center for genodermatoses and rare skin diseases - vascular anomalies (MAGEC), 37000 Tours, France
| | - A Marchand
- University Hospital Center of Tours (CHRU), Department of Dermatology, Unit of Pediatric Dermatology, 37044 Tours Cedex 9, France; CHRU Tours, Reference center for genodermatoses and rare skin diseases - vascular anomalies (MAGEC), 37000 Tours, France; CHRU Tours, Clinical Investigation Center-Inserm 1415, 37000 Tours, France
| | - J Mazereeuw-Hautier
- Department of Dermatology and Reference center for genodermatoses and rare skin diseases (MAGEC), Hospital Larrey, University Hospital Center of Toulouse, 31059 Toulouse Cedex 9, France
| | - O Boccara
- Department of Dermatology and Reference center for genodermatoses and rare skin diseases (MAGEC), France Université Paris, Paris-centre, Institut Imagine, Hôpital Universitaire Necker-Enfants Malades, AP-HP, 75015 Paris, France
| | - L Martin
- Department of Dermatology, University Hospital Center of Angers, 49000 Angers, France
| | - C Chiaverini
- Department of Dermatology, University Hospital Center of Nice, 06000 Nice, France
| | - N Beneton
- Department of Dermatology, Hospital Center of le Mans, 72000 Le Mans, France
| | - P Vabres
- Department of Dermatology, University Hospital Center of Dijon, Reference center for genodermatoses and rare skin diseases (MAGEC), 21000 Dijon, France
| | - X Balguerie
- Department of Dermatology, University Hospital Center of Rouen, 76000 Rouen, France
| | - P Plantin
- Department of Dermatology, Hospital Center of Quimper, 29000 Quimper, France
| | - D Bessis
- Department of Dermatology, University Hospital Center of Montpellier, 34000 Montpellier, France
| | - S Barbarot
- Department of Dermatology, University Hospital Center of Nantes, 44000 Nantes, France
| | - A Dadban
- Department of Dermatology, University Hospital Center of Amiens, 80000 Amiens, France
| | - C Droitcourt
- Department of Dermatology, University Hospital Center of Rennes, 35000 Rennes, France
| | - M Samimi
- University Hospital Center of Tours (CHRU), Department of Dermatology, Unit of Pediatric Dermatology, 37044 Tours Cedex 9, France
| | - B Morel
- CHRU Tours, Reference center for genodermatoses and rare skin diseases - vascular anomalies (MAGEC), 37000 Tours, France; CHRU Tours, Department of Pediatric Radiology, 37000 Tours, France
| | - A Caille
- CHRU Tours, Clinical Investigation Center-Inserm 1415, 37000 Tours, France; Universities of Tours and Nantes, SPHERE-INSERM 1246, 37000 Tours, France
| | - A Maruani
- University Hospital Center of Tours (CHRU), Department of Dermatology, Unit of Pediatric Dermatology, 37044 Tours Cedex 9, France; CHRU Tours, Reference center for genodermatoses and rare skin diseases - vascular anomalies (MAGEC), 37000 Tours, France; CHRU Tours, Clinical Investigation Center-Inserm 1415, 37000 Tours, France; Universities of Tours and Nantes, SPHERE-INSERM 1246, 37000 Tours, France
| | - S Leducq
- University Hospital Center of Tours (CHRU), Department of Dermatology, Unit of Pediatric Dermatology, 37044 Tours Cedex 9, France; CHRU Tours, Reference center for genodermatoses and rare skin diseases - vascular anomalies (MAGEC), 37000 Tours, France; Universities of Tours and Nantes, SPHERE-INSERM 1246, 37000 Tours, France.
| | | |
Collapse
|
6
|
Skowron F, Mouret S, Seigneurin A, Montaudié H, Maubec E, Grange F, Quéreux G, Celerier P, Adle A, Dalac S, De Quatrebarbes J, Zehou O, Safia A, Muller P, Modiano P, Misery L, Litrowski N, Brunet Possenti F, Mortier L, Bens G, Hervieu A, Leduc N, Jouary T, Lesage C, Beneton N, Le Corre Y, Geoffrois L, Thomas-Beaulieu D, Khammari A, Wierzbicka-Hainaut E, Leccia M. La pandémie COVID-19 est associée à des mélanomes diagnostiqués à un stade plus avancé. Annales de Dermatologie et de Vénéréologie - FMC 2022. [PMCID: PMC9748166 DOI: 10.1016/j.fander.2022.09.173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
7
|
Curmin R, Guillo S, De Rycke Y, Bachelez H, Beylot‐Barry M, Beneton N, Chosidow O, Dupuy A, Joly P, Jullien D, Richard M, Viguier M, Sbidian E, Paul C, Mahé E, Tubach F. Switches between biologics in patients with moderate-to-severe psoriasis: results from the French cohort PSOBIOTEQ. J Eur Acad Dermatol Venereol 2022; 36:2101-2112. [PMID: 35793473 PMCID: PMC9796114 DOI: 10.1111/jdv.18409] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2022] [Accepted: 05/18/2022] [Indexed: 01/01/2023]
Abstract
BACKGROUND Biologics are the cornerstone of treatment of patients with moderate-to-severe plaque psoriasis and switches between biologics are frequently needed to maintain clinical improvement over time. OBJECTIVES The main purpose of this study was to describe precisely switches between biologics and how their pattern changed over time with the recent availability of new biologic agents. METHODS We included patients receiving a first biologic agent in the Psobioteq multicenter cohort of adults with moderate-to-severe psoriasis receiving systemic treatment. We described switches between biologics with chronograms, Sankey and Sunburst diagrams, assessed cumulative incidence of first switch by competing risks survival analysis and reasons for switching. We assessed the factors associated with the type of switch (intra-class - i.e. within the same therapeutic class - vs. inter-class) in patients switching from a TNF-alpha inhibitor using multivariate logistic regression. RESULTS A total of 2153 patients was included. The cumulative incidence of switches from first biologic was 34% at 3 years. Adalimumab and ustekinumab were the most prescribed biologic agents as first and second lines of treatment. The main reason for switching was loss of efficacy (72%), followed by adverse events (11%). Patients receiving a TNF-alpha inhibitor before 2016 mostly switched to ustekinumab, whereas those switching in 2016 or after mostly switched to an IL-17 inhibitor. Patients switching from a first-line TNF-alpha inhibitor before 2016 were more likely to switch to another TNF-alpha inhibitor compared with patients switching since 2018. Patients switching from etanercept were more likely to receive another TNF-alpha inhibitor rather than another therapeutic class of bDMARD compared with patients switching from adalimumab. CONCLUSION This study described the switching patterns of biologic treatments and showed how they changed over time, due to the availability of the new biologic agents primarily IL-17 inhibitors.
Collapse
Affiliation(s)
- R. Curmin
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé PubliqueParisFrance
| | - S. Guillo
- INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP‐HP, Hôpital Pitié Salpêtrière, Département de Santé Publique, Centre de Pharmacoépidémiologie (Cephepi)Sorbonne UniversitéParisFrance
| | - Y. De Rycke
- INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP‐HP, Hôpital Pitié Salpêtrière, Département de Santé Publique, Centre de Pharmacoépidémiologie (Cephepi)Sorbonne UniversitéParisFrance
| | - H. Bachelez
- Dermatologie, AP‐HP Hôpital Saint LouisParisFrance,Sorbonne Paris Cité Universitaire Paris DiderotParisFrance,UMR INSERM 1163, Institut ImagineParisFrance
| | - M. Beylot‐Barry
- Dermatologie CHU Bordeaux & INSERM U 1053Bordeaux UniversityBordeauxFrance
| | | | - O. Chosidow
- Dermatologie, AP‐HP, Hôpitaux universitaires Henri Mondor, Département de Dermatologie, UPEC, INSERM, Centre d'Investigation Clinique 1430, EA 7379 EpidermEUniversité Paris‐Est Créteil, UPECCréteilFrance
| | - A. Dupuy
- DermatologieCHU PontchaillouRennesFrance
| | - P. Joly
- DermatologieCHU RouenRouenFrance
| | - D. Jullien
- Dermatologie, Hospices Civils de Lyon, Hôpital E. HerriotUniversité Lyon‐1LyonFrance
| | - M.A. Richard
- Dermatologie, EA 3279: CEReSS ‐ Health Service Research and Quality of Life Center, Timone Hospital, Assistance Publique Hôpitaux de MarseilleAix‐Marseille UniversityMarseilleFrance
| | - M. Viguier
- Dermatologie‐VénéréologieHôpital Robert DebréReimsFrance
| | - E. Sbidian
- Dermatologie, AP‐HP, Hôpitaux universitaires Henri Mondor, Département de Dermatologie, UPEC, INSERM, Centre d'Investigation Clinique 1430, EA 7379 EpidermEUniversité Paris‐Est Créteil, UPECCréteilFrance
| | - C. Paul
- DermatologieCHU and Toulouse UniversityToulouseFrance
| | - E. Mahé
- DermatologieHôpital Victor DupouyArgenteuilFrance
| | - F. Tubach
- INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP‐HP, Hôpital Pitié Salpêtrière, Département de Santé Publique, Centre de Pharmacoépidémiologie (Cephepi)Sorbonne UniversitéParisFrance
| | | |
Collapse
|
8
|
Curmin R, Guillo S, De Rycke Y, Bachelez H, Beylot-Barry M, Beneton N, Olivier C, Dupuy A, Joly P, Jullien D, Richard M, Viguier M, Sbidian E, Paul C, Mahé E, Tubach F. Switchs de biothérapies chez les patients atteints de psoriasis modéré à sévère dans la cohorte française PSOBIOTEQ. Rev Epidemiol Sante Publique 2022. [DOI: 10.1016/j.respe.2022.03.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
9
|
Aubert H, Mahé E, Fougerousse AC, Maccari F, Beneton N. Dose spacing and reduction strategies in biotherapies for stable, clear or almost clear psoriasis: A survey of practices in France. Ann Dermatol Venereol 2021; 149:68-70. [PMID: 34887084 DOI: 10.1016/j.annder.2021.07.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2021] [Revised: 05/12/2021] [Accepted: 07/01/2021] [Indexed: 11/26/2022]
Affiliation(s)
- H Aubert
- Department of Dermatology, Centre Hospitalier Universitaire, 1, avenue Alexis-Ricordeau, 44000 Nantes, France.
| | - E Mahé
- Department of Dermatology, Hôpital Victor Dupouy, 69, rue du Lieutenant-Colonel Prud'hon, 95100 Argenteuil, France
| | - A-C Fougerousse
- Department of Dermatology, 69, Avenue de Paris, 94160 Saint-Mandé, France
| | | | - N Beneton
- Department of Dermatology, Centre Hospitalier, 194, Avenue Rubillard, 72037 Le Mans, France
| | | |
Collapse
|
10
|
Say M, Tella E, Boccara O, Sauvage M, Bourrat E, Tian Y, Monfort JB, Lok C, Desierier F, Beneton N, Abasq-Thomas C, Kupfer-Bessaguet I, Mallet S, Lacour JP, Plantin P, Sigal ML, Mazereeuw-Hautier J, Mahé E. Leg ulcers in childhood: A multicenter study in France. Ann Dermatol Venereol 2021; 149:51-55. [PMID: 34218940 DOI: 10.1016/j.annder.2021.05.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2021] [Revised: 03/30/2021] [Accepted: 05/19/2021] [Indexed: 11/27/2022]
Abstract
BACKGROUND Leg ulcers in adults are a major public health concern. Their incidence increases with age and many causes have been identified, predominantly associated with vascular diseases. Leg ulcers in children and teenagers are less frequent. The aim of our study was to identify the causes of leg ulcers in children and teenagers, and to evaluate their management. METHODS This retrospective multicenter study was conducted by members of the Angio-dermatology Group of the French Society of Dermatology and of the French Society of Pediatric Dermatology. Data from children and teenagers (< 18 years), seen between 2008 and 2020 in 12 French hospitals for chronic leg ulcer (disease course>4 weeks), were included. RESULTS We included 27 patients, aged from 2.3 to 17.0 years. The most frequent causes of leg ulcer were: general diseases (n=9: pyoderma gangrenosum, dermatomyositis, interferonopathy, sickle cell disease, prolidase deficiency, scleroderma, Ehlers-Danlos syndrome), vasculopathies (n=8: hemangioma, capillary malformation, arteriovenous malformation), trauma (n=4: bedsores, pressure ulcers under plaster cast), infectious diseases (n=4: pyoderma, tuberculosis, Buruli ulcer) and neuropathies (n=2). Comorbidities (59.3%) and chronic treatments (18.5%) identified as risk factors for delayed healing were frequent. The average time to healing was 9.1 months. DISCUSSION Leg ulcers are less frequent in children and teenagers than in adults and their causes differ from those in adults. Comorbidities associated with delayed healing must be identified and managed. Children and teenagers tend to heal faster than adults, but a multidisciplinary management approach is necessary.
Collapse
Affiliation(s)
- M Say
- Service de dermatologie et médecine vasculaire, hôpital Victor-Dupouy, 69, rue du Lieutenant-Colonel Prud'hon, 95100 Argenteuil, France.
| | - E Tella
- Service de dermatologie et médecine vasculaire, hôpital Victor-Dupouy, 69, rue du Lieutenant-Colonel Prud'hon, 95100 Argenteuil, France
| | - O Boccara
- Service de dermatologie, centre hospitalier universitaire Necker-Enfants Malades, AP-HP, Paris, France
| | - M Sauvage
- Service de dermatologie, centre de référence des Maladies Rares de la Peau, centre hospitalier universitaire Larrey, Université Paul-Sabatier, Toulouse, France
| | - E Bourrat
- Service de pédiatrie générale, centre hospitalier universitaire Robert-Debré, AP-HP, Paris, France
| | - Y Tian
- Service de pédiatrie générale, centre hospitalier universitaire Robert-Debré, AP-HP, Paris, France
| | - J-B Monfort
- Service de dermatologie, centre hospitalier universitaire Tenon, AP-HP, Paris, France
| | - C Lok
- Service de dermatologie, centre hospitalier universitaire Amiens-Picardie, Amiens, France
| | - F Desierier
- Service de dermatologie, centre hospitalier universitaire Amiens-Picardie, Amiens, France
| | - N Beneton
- Service de dermatologie, centre hospitalier du Mans, Le Mans, France
| | - C Abasq-Thomas
- Service de dermatologie, centre hospitalier Régional Universitaire de Brest, Brest, France
| | | | - S Mallet
- Service de dermatologie, centre hospitalier universitaire La Timone, Assistance Publique des Hôpitaux de Marseille, Marseille, France
| | - J-P Lacour
- Service de dermatologie, centre hospitalier universitaire L'archet, Nice, France
| | - P Plantin
- Service de dermatologie, centre hospitalier de Cornouaille, Quimper, France
| | - M-L Sigal
- Service de dermatologie et médecine vasculaire, hôpital Victor-Dupouy, 69, rue du Lieutenant-Colonel Prud'hon, 95100 Argenteuil, France
| | - J Mazereeuw-Hautier
- Service de dermatologie, centre de référence des Maladies Rares de la Peau, centre hospitalier universitaire Larrey, Université Paul-Sabatier, Toulouse, France
| | - E Mahé
- Service de dermatologie et médecine vasculaire, hôpital Victor-Dupouy, 69, rue du Lieutenant-Colonel Prud'hon, 95100 Argenteuil, France
| | | |
Collapse
|
11
|
Beylot-Barry M, Seneschal J, Tran D, Bachelez H, Beneton N, Dupuy A, Joly P, Jullien D, Mahé E, Paul C, Richard MA, Sbidian E, Viguier M, Chosidow O, Tubach F. Characteristics of patients with psoriasis with Psoriasis Area and Severity Index < 10 treated with biological agents: results from the French PsoBioTeq cohort. Br J Dermatol 2021; 185:1052-1054. [PMID: 34128543 DOI: 10.1111/bjd.20585] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2021] [Revised: 06/13/2021] [Accepted: 06/13/2021] [Indexed: 01/20/2023]
Affiliation(s)
- M Beylot-Barry
- Dermatology Department, Bordeaux University Hospital, Bordeaux, France
| | - J Seneschal
- Dermatology Department, Bordeaux University Hospital, Bordeaux, France
| | - D Tran
- INSERM, Pierre Louis Institute for Epidemiology and Public Health, AP-HP, Paris, France.,Sorbonne University, Pitié Salpêtrière Hospitals, Public Health Department, Pharmacoepidemiology Centre, CIC-1422, Paris, France
| | - H Bachelez
- Dermatology Department, Saint-Louis Hospital, AP-HP, Université de Paris, Paris, France
| | - N Beneton
- Dermatology Department, Le Mans Hospital, Le Mans, France
| | - A Dupuy
- Dermatology Department, Rennes University Hospital, Rennes, France
| | - P Joly
- Dermatology Department, Rouen University Hospital, Rouen, France
| | - D Jullien
- Dermatology Department, Edouard Herriot Hospital, Lyon, France
| | - E Mahé
- Dermatology Department, Victor Dupouy Hospital, Argenteuil, France
| | - C Paul
- Dermatology Department, Toulouse University and University Hospital, Toulouse, France
| | - M-A Richard
- Dermatology Department, Marseille University Hospital, Marseille, France
| | - E Sbidian
- Dermatology Department, AP-HP, Henri Mondor University Hospitals, Paris-Est Créteil University, INSERM CIC1430, Créteil, France.,EpiDermE EA7379, Créteil, France
| | - M Viguier
- Dermatology-Venereology Department, Reims University Hospital, Reims, France
| | - O Chosidow
- Dermatology Department, AP-HP, Henri Mondor University Hospitals, Paris-Est Créteil University, INSERM CIC1430, Créteil, France.,Research Group Dynamic, EA7380, Créteil Health Faculty, Alfort National Veterinary School, USC ANSES, Paris-Est Créteil University, Créteil, France
| | - F Tubach
- INSERM, Pierre Louis Institute for Epidemiology and Public Health, AP-HP, Paris, France.,Sorbonne University, Pitié Salpêtrière Hospitals, Public Health Department, Pharmacoepidemiology Centre, CIC-1422, Paris, France
| |
Collapse
|
12
|
Fredeau L, Hober C, Pham-Ledard A, Boubaya M, Herms F, Celerier P, Aubin F, Beneton N, Dinulescu M, Jannic A, Meyer N, Duval Modeste AB, Cesaire L, Neidhardt EM, Archier E, Dreno B, Lesage C, Berthin C, Kramkimel N, Grange F, De Quatrebarbes J, Stoebner P, Poulalhon N, Arnault J, Abed S, Bonniaud B, Darras S, Heidelberger V, Devaux S, Moncourier M, Misery L, Mansard S, Etienne M, Brunet-Possenti F, Jacobzone C, Lesbazeilles R, Skowron F, Sanchez J, Catala S, Samimi M, Tazi Y, Spaeth D, Gaudy-Marqueste C, Collard O, Triller R, Pracht M, Dumas M, Peuvrel L, Combe P, Lauche O, Guillet P, Reguerre Y, Kupfer-Bessaguet I, Solub D, Schoeffler A, Bedane C, Dalac S, Mortier L, Maubec E. Cémiplimab et carcinomes épidermoïdes cutanés localement évolués ou métastatiques : premières données de vie réelle. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
13
|
Robert J, Marchand A, Mazereeuw-Hautier J, Boccara O, Martin L, Chiaverini C, Beneton N, Vabres P, Balguerie X, Plantin P, Bessis D, Barbarot S, Dadban A, Droitcourt C, Morel B, Leducq S, Samimi M, Caille A, Maruani A. Qualité de vie chez les enfants ayant une malformation capillaire de membre inférieur : données dynamiques sur 5 ans (cohorte nationale multicentrique CONAPE). Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
14
|
Say M, Tella E, Boccara O, Mazereeuw Hautier J, Sauvage M, Bourrat E, Tian Y, Montfort J, Lok C, Dessierier F, Beneton N, Abasaq Thomas C, Kupfer-Bessaguet I, Mallet S, Lacour J, Plantin P, Sigal M, Mahé E. Ulcères de membres inférieurs chez les enfants et les adolescents : étude multicentrique française. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
15
|
Grodner C, Beauchet A, Fougerousse A, Quiles‐Tsimaratos N, Perrot J, Barthelemy H, Parier J, Maccari F, Beneton N, Bouilly‐Auvray D, Ruer‐Mulard M, Boulard C, Jacobzone C, Thomas‐Beaulieu D, Pourchot D, Méry‐Bossard L, Chaby G, Girard C, Duval‐Modeste A, Vermersch‐Langlin A, Delaunay J, Marc S, Kemula M, Steff M, Bilan P, Liégeon A, Aubert H, Solyga B, Kluger N, Mahé E. Tattoo complications in treated and non‐treated psoriatic patients. J Eur Acad Dermatol Venereol 2020; 34:888-896. [DOI: 10.1111/jdv.15975] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2019] [Accepted: 09/04/2019] [Indexed: 11/27/2022]
Affiliation(s)
- C. Grodner
- Dermatology Department Hôpital Victor Dupouy Argenteuil France
| | - A. Beauchet
- Public Health Department Hôpital Ambroise Paré Boulogne‐Billancourt France
| | - A.‐C. Fougerousse
- Dermatology Department Hôpital d'Instruction des Armées Bégin Saint Mandé France
| | | | - J.‐L. Perrot
- Dermatology Department CHU Saint‐Etienne Saint‐Etienne France
| | - H. Barthelemy
- Dermatology Department Centre Hospitalier d'Auxerre Auxerre France
| | - J. Parier
- Private Office La Varenne St Hilaire France
| | - F. Maccari
- Private Office La Varenne St Hilaire France
| | - N. Beneton
- Dermatology Department Centre Hospitalier du Mans Le Mans France
| | - D. Bouilly‐Auvray
- Dermatology Department Centre Hospitalier Universitaire de Dijon Dijon France
| | | | - C. Boulard
- Dermatology Department Hôpital Jacques Monod Le Havre Cedex France
| | - C. Jacobzone
- Dermatology Department Centre Hospitalier de Lorient Lorient France
| | - D. Thomas‐Beaulieu
- Dermatology Department Centre Hospitalier Intercommunal de Poissy/Saint‐Germain‐en‐Laye Saint‐Germain‐en‐Laye France
| | - D. Pourchot
- Dermatology Department Centre Hospitalier Intercommunal de Poissy/Saint‐Germain‐en‐Laye Saint‐Germain‐en‐Laye France
| | - L. Méry‐Bossard
- Dermatology Department Centre Hospitalier Intercommunal de Poissy/Saint‐Germain‐en‐Laye Saint‐Germain‐en‐Laye France
| | - G. Chaby
- Dermatology Department Hôpital Sud Amiens France
| | - C. Girard
- Dermatology Department Centre Hospitalier Universitaire de Montpellier Montpellier France
| | - A.‐B. Duval‐Modeste
- Dermatology Department Centre Hospitalier Universitaire Charles‐Nicolle Rouen France
| | | | | | - S. Marc
- Dermatology Department Hôpital François Quesnay Mantes La Jolie France
| | | | - M. Steff
- Dermatology Department Hôpital Intercommunal Robert‐Ballanger Aulnay‐sous‐Bois France
| | - P. Bilan
- Dermatology Department Hôpital Intercommunal Robert‐Ballanger Aulnay‐sous‐Bois France
| | - A.‐L. Liégeon
- Dermatology Department Hôpital de Valence Valence France
| | - H. Aubert
- Dermatology Department Centre Hospitalier Universitaire de Nantes Nantes France
| | - B. Solyga
- Private Office Fontenay‐sous‐Bois France
| | - N. Kluger
- Dermatology Department, Allergology, and Venereology University of Helsinki and Helsinki University Central Hospital Helsinki Finland
- Dermatology Department Tattoo Consultation Centre Hospitalier Universitaire Bichat‐Claude Bernard Assistance Publique‐Hôpitaux de Paris Paris France
| | - E. Mahé
- Dermatology Department Hôpital Victor Dupouy Argenteuil France
| | | |
Collapse
|
16
|
Phan C, Delaunay J, Beneton N, Reguiai Z, Boulard C, Fougerousse A, Cinotti E, Romanelli M, Mery Bossard L, Thomas-Beaulieu D, Parier J, Perrot JL, Ruer-Mulard M, Bastien M, Begon E, Samimi M, Jacobzone C, Quiles-Tsimaratos N, Descamps V, Steff M, Bilan P, Vermersch-Langlin A, Kemula M, Amazan E, Kupfer-Bessaguet I, Cottencin AC, Prignano F, Bulai Livideanu C, Gottlieb J, Beauchet A, Mahé E. Tolérance et efficacité de l’aprémilast chez les patients psoriasiques de plus de 65 ans. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
17
|
Lechevalier D, Denis D, Le Corre Y, Brunet-Possenti F, Heidelberger V, Longvert C, Maillard H, Beneton N. Syndrome du canal carpien sous inhibiteurs de check-points immunitaires : 10 cas. Un nouvel effet secondaire immunologique ? Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
18
|
Fougerousse AC, Reguiai Z, Maccari F, Parier J, Schmutz JL, Begon E, Chaby G, Bouilly-Auvray D, Pallure V, Beneton N, Monfort JB, Boulard C, Delaunay J, Clément Lepley C, Bastien M, Mery Bossard L, Perrot JL, Jacobzone C, Vermersch A, Esteve E. Profil des patients à l’initiation du guselkumab : étude rétrospective multicentrique. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.526] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
19
|
Masson Regnault M, Castañeda-Sanabria J, Diep Tran MHT, Beylot-Barry M, Bachelez H, Beneton N, Chosidow O, Dupuy A, Joly P, Jullien D, Mahé E, Richard MA, Viguier M, Tubach F, Sbidian E, Paul C. Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort Study in the French Psoriasis Registry PSOBIOTEQ. J Eur Acad Dermatol Venereol 2019; 34:293-300. [PMID: 31419355 DOI: 10.1111/jdv.15878] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2019] [Accepted: 07/17/2019] [Indexed: 01/10/2023]
Abstract
BACKGROUND Numerous inclusion and exclusion criteria are involved in phase III moderate to severe psoriasis trials investigating the safety and efficacy of biologics. This questions the generalization of results. METHODS In this cohort study, we applied inclusion/exclusion criteria for phase III trials from original protocols (adalimumab - REVEAL, ustekinumab - PHOENIX, brodalumab - AMAGINE, secukinumab FIXTURE) to all patients enrolled in the PsoBioTeq prospective registry who received a biological agent for the first time between July 2012 and November 2017. We then compared the efficacy, drug survival and occurrence of adverse events between patients who satisfied/did not satisfy the eligibility criteria for these phase III trials. RESULTS A total of 1267 patients were enrolled, of whom 993 (78.4%) were not eligible for at least one RCT (randomized controlled trial) and 251 (19.1%) did not meet the PASI/PGA severity requirements. Apart from disease severity, the most frequent criteria resulting in exclusion were as follows: non-plaque psoriasis (12.6%), significant cardiac disease (8.4%), significant liver disease (7.3%), elevated liver enzymes (4.9-9.6%) and personal history of diabetes (9.2%). There was no difference in drug survival between the two groups. The incidence ratio of adverse events was significantly lower in eligible versus non-eligible patients [0.78 (95% CI 0.62-0.97) (P = 0.03)]. CONCLUSION The majority of patients treated with biologics in the PsoBioTeq real-life registry would not have been eligible for phase III moderate to severe psoriasis trials. Patients not eligible for psoriasis phase III clinical trials have a higher incidence of adverse events.
Collapse
Affiliation(s)
| | | | - M H T Diep Tran
- Centre de Pharmaco-épidémiologie, Pitié Salpêtrière, Paris, France
| | | | - H Bachelez
- Service de Dermatologie, AP-HP Hopital Saint Louis, Paris, France.,Sorbonne Paris Cité Université Paris Diderot, Paris, France.,UMR INSERM 1163, Institut Imagine, Paris, France
| | - N Beneton
- Dermatologie, CHU Le Mans, Le Mans, France
| | - O Chosidow
- Dermatologie, AP-HP, Hôpitaux universitaires Henri Mondor, Département de Dermatologie, UPEC, INSERM, Centre d'Investigation Clinique 1430, EA 7379 EpidermE, Université Paris-Est Créteil, UPEC, Créteil, France
| | - A Dupuy
- Dermatologie, CHU Rennes, Rennes, France
| | - P Joly
- Dermatologie, CHU Rouen, Rouen, France
| | - D Jullien
- Dermatologie, CHU Lyon, Lyon, France
| | - E Mahé
- Dermatologie, CH Argenteuil, Argenteuil, France
| | - M-A Richard
- Dermatology Department, EA 3279: CEReSS - Health Service Research and Quality of Life Center, Timone Hospital, Assistance Publique Hôpitaux de Marseille, Aix-Marseille University, Marseille, France
| | - M Viguier
- Dermatologie-Vénéréologie, Hôpital Robert Debré, Reims, France
| | - F Tubach
- Centre de Pharmaco-épidémiologie, Pitié Salpêtrière, Paris, France.,Sorbonne Université, INSERM UMR-S 1136, Paris, France
| | - E Sbidian
- Dermatologie, AP-HP, Hôpitaux universitaires Henri Mondor, Département de Dermatologie, UPEC, INSERM, Centre d'Investigation Clinique 1430, EA 7379 EpidermE, Université Paris-Est Créteil, UPEC, Créteil, France
| | - C Paul
- Dermatologie, CHU Toulouse, Toulouse, France
| | | |
Collapse
|
20
|
Tournier A, Khemis A, Maccari F, Reguiai Z, Bégon E, Fougerousse AC, Amy de la Breteque M, Beneton N, Parier J, Boyé T, Avenel-Audran M, Girard C, Pallure V, Perrot JL, Bastien M, Mahé E, Beauchet A. Methotrexate efficacy and tolerance in plaque psoriasis. A prospective real-life multicentre study in France. Ann Dermatol Venereol 2019; 146:106-114. [DOI: 10.1016/j.annder.2018.11.011] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2018] [Revised: 08/28/2018] [Accepted: 11/21/2018] [Indexed: 12/28/2022]
|
21
|
Chassaint K, Prophete B, Lamy J, Batistella M, Lemaire P, Celerier P, Beneton N. Xanthomes tumoraux péri-ophtalmiques et cytopénie : quel trouble lipidique évoquer ? Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.401] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
22
|
Masson Regnault M, Castaneda Sanabria J, Tran M, Beylot-Barry M, Bachelez H, Beneton N, Chosidow O, Dupuy A, Joly P, Jullien D, Mahé E, Richard MA, Viguier M, Tubach F, Sbidian E, Paul C. Les patients de la vraie vie peuvent-ils être inclus dans les études cliniques évaluant des biologiques ? Analyse dans la cohorte PsoBioTeq. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
23
|
Giraud S, Samimi M, Gaboriaud P, Arnold F, Kervarrec T, Wierzbicka-Hainaut E, Bens G, Beneton N, Aubin F, Dréno B, Laude H, Avril M, Dupin N, Dinulescu M, Le Corre Y, Blom A, Maubec E, Guyetant S, Touzé A. Sérologie anti-antigène T du polyomavirus de Merkel dans la surveillance des patients ayant un carcinome de Merkel : étude rétrospective multicentrique. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
24
|
Chaplain L, Blom A, Samimi M, Guillot B, Jouary T, Grob JJ, Meyer N, Zehou O, Combemale P, Lebbé C, Jeudy G, Grange F, Lacour P, Dinulescu M, Granel Brocard F, Beneton N, Aubin F, Bens G, De Quatrebarbes J, Steff M, Arnault JP, Le Corre Y, Stefan A, D’Incan M, Kramkimel N, Leccia MT, Thomas Beaulieu D, Maubec E, Robert C, Dreno B, Wierzbicka-Hainaut E, Lenormand C, Saiag P, Mortier L. Carcinome de Merkel : état des lieux du réseau CARADERM. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
25
|
Fougerousse A, Guillem P, Allal S, Maccari F, Beneton N, Binois R, Cinotti E, Cambazard F, Perrot JL. Influence de l’ancienneté de la maladie de Verneuil sur la qualité de vie et la douleur à propos de 1428 sujets : étude EpiVer. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
26
|
Husson B, Barbe C, Hegazy S, Seneschal J, Aubin F, Mahé E, Jullien D, Sbidian E, d’Incan M, Conrad C, Brénault E, Girard C, Avenel-Audran M, Le Maître M, Modiano P, Quiles N, Zaraa I, Richard MA, Goujon C, Beneton N, Destoop J, Bachelez H, Viguier M. Efficacité et tolérance des traitements systémiques conventionnels dans le traitement du psoriasis pustuleux acral : étude française rétrospective sur 205 patients. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
27
|
Law S, Droitcourt C, Bouzillé G, Safa G, Beneton N, Dupuy A. Première ligne de traitement systémique dans la dermatite atopique modérée à sévère : comparaison longitudinale des profils d’utilisation (« drug survival », « post-drug survival ») du méthotrexate et de la ciclosporine. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
28
|
Begon E, Beneton N, Poiraud C, Droitcourt C, Jacobzone C, Vermersch-Langlin A, Descamps V, Perrot JL, Khemis A, Pallure V, Fougerousse AC, Sigal-Grinberg M, Schmutz JL, Goujon C, Reguiai Z. Safety and efficacy of biological therapies in patients with psoriasis with alcoholic cirrhosis: a French retrospective study of 23 cases. Br J Dermatol 2018; 179:512-513. [PMID: 29480522 DOI: 10.1111/bjd.16490] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- E Begon
- Hôpital René Dubos - Dermatology, 6 Avenue de l'Ile de France, Pontoise, 95300, France
| | - N Beneton
- Department of Dermatology, Le Mans Hospital, Le Mans, France
| | - C Poiraud
- Centre Hospitalier Départemental Vendée - Dermatologie, La Roche-sur-Yon, France
| | - C Droitcourt
- Department of Dermatology, Rennes-1 University Hospital, Rennes, France
| | - C Jacobzone
- Centre Hospitalier de Bretagne Sud, Lorient, France
| | | | - V Descamps
- Department of Dermatology, Hôpital Bichat - Claude-Bernard, Paris, France
| | - J L Perrot
- Department of Dermatology, University Hospital of Saint-Etienne, Saint-Priest-en-Jarez, France
| | - A Khemis
- Department of Dermatology, Centre Hospitalier Universitaire de Nice, Nice, France
| | - V Pallure
- Department of Dermatology, University Hospital Montpellier, Montpellier, France
| | - A C Fougerousse
- Department of Dermatology, Hôpital d'Instruction des Armées Begin, Saint Mande, France
| | - M Sigal-Grinberg
- Department of Dermatology, Hôpital Victor Dupouy, 95100, Argenteuil, France
| | - J-L Schmutz
- Department of Dermatology, Fournier Hospital, 36 Quai de la Bataille, Nancy, 54000, France
| | - C Goujon
- Hospices Civils de Lyon - Allergology and Clinical Immunology, Centre Hospitalier Lyon Sud Bâtiment 1K, Pierre-Bénite 69495, France
| | - Z Reguiai
- Department of Dermatology, Polyclinique de Courlancy, Reims, France
| | | |
Collapse
|
29
|
Polivka L, Oubaya N, Bachelez H, Paul C, Richard MA, Beylot-Barry M, Schmutz JL, Beneton N, Mahé E, Viguier M, Chosidow O, Canoui-Poitrine F, Sbidian E. Trends in hospitalization rates for psoriasis flares since the introduction of biologics: a time series in France between 2005 and 2015. J Eur Acad Dermatol Venereol 2018; 32:1920-1929. [PMID: 29729123 DOI: 10.1111/jdv.15044] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2018] [Accepted: 03/28/2018] [Indexed: 11/28/2022]
Abstract
BACKGROUND In the late 2000s, the introduction of biologics transformed the prognosis for patients with moderate-to-severe psoriasis. We hypothesized that treatment with biologics may associate with a reduction in the hospitalization rate for psoriasis flares. OBJECTIVE To analyse changes over time in the hospitalization rate for psoriasis flares. METHODS We included inpatient stays in any of nine French hospitals between 2005 and 2015 for a psoriasis flare, as documented in the national inpatient database. In two centres, we also analysed data from the individual patients' electronic medical records. RESULTS A total of 3572 stays were included. The introduction of biologics was not associated with a decrease in the number of hospitalizations for a psoriasis flare; on the contrary, we observed a non-significant increase in the number of hospitalizations (13 hospitalizations for psoriasis flares per quarter per 10 000 beds). In the two-centre study, the introduction of biologics was associated with a significant increase in the hospitalization of patients receiving topical treatments only (520 hospitalizations per year per 10 000 beds) and those with a first psoriasis flare. CONCLUSION The number of hospitalizations for a psoriasis flare tended to increase between 2005 and 2015. The availability of additional treatment options might have increased patient demand and/or broadened the indications in clinical practice.
Collapse
Affiliation(s)
- L Polivka
- Department of Dermatology, Necker-Enfants Malades Hospital (AP-HP), Paris Descartes-Sorbonne Paris Cité University, Paris, France
| | - N Oubaya
- Department of Clinical Research and Public Health, Mondor Hospital (AP-HP), Paris Est Créteil University, Créteil, France.,IMRB-EA 7376 CEpiA (Clinical Epidemiology And Ageing Unit), UPEC, DHU A-TVB, Paris-Est University, Créteil, France
| | - H Bachelez
- Department of Dermatology, Saint Louis Hospital (AP-HP), Sorbonne Paris Cité University Paris Diderot, Paris, France
| | - C Paul
- Department of Dermatology, Larrey Hospital, Toulouse University, Toulouse, France
| | - M A Richard
- Dermatology Department, Centre de recherche en oncologie biologique et oncophamacologie', UMR 911, INSERM CRO2, Timone Hospital, Assistance Publique Hôpitaux de Marseille, Aix-Marseille Univ, Marseille, France
| | - M Beylot-Barry
- Department of Dermatology, INSERM 1053, CHU Bordeaux, Bordeaux University, Bordeaux, France
| | - J L Schmutz
- Department of Dermato-Allergology, Brabois Hospital, Nancy University, Vandoeuvre-lès-Nancy, France
| | - N Beneton
- Department of Dermatology, Le Mans General Hospital, Le Mans, France
| | - E Mahé
- Department of Dermatology, Victor Dupouy Hospital, Argenteuil, France
| | - M Viguier
- Department of Dermatology, Robert Debré Hospital, University of Reims-Champagne Ardennes, Reims, France
| | - O Chosidow
- Department of Dermatology, Mondor Hospital (AP-HP), Paris Est Créteil University, Créteil, France.,Centre d'Investigation Clinique 1430, INSERM, Créteil, France.,UPEC, DHU VIC, EA 7379 EpiDermE (Epidemiologie En Dermatologie et Evaluation des Thérapeutiques), Paris-Est University, Créteil, France
| | - F Canoui-Poitrine
- Department of Clinical Research and Public Health, Mondor Hospital (AP-HP), Paris Est Créteil University, Créteil, France.,IMRB-EA 7376 CEpiA (Clinical Epidemiology And Ageing Unit), UPEC, DHU A-TVB, Paris-Est University, Créteil, France
| | - E Sbidian
- Department of Dermatology, Mondor Hospital (AP-HP), Paris Est Créteil University, Créteil, France.,Centre d'Investigation Clinique 1430, INSERM, Créteil, France.,UPEC, DHU VIC, EA 7379 EpiDermE (Epidemiologie En Dermatologie et Evaluation des Thérapeutiques), Paris-Est University, Créteil, France
| | | |
Collapse
|
30
|
Loget J, Saint-Martin C, Guillem P, Kanagaratnam L, Becherel PA, Nassif A, Fougerousse AC, Siham M, Girard C, Barthelemy H, Chaby G, Gabison G, Perrot JL, Pallure V, Beneton N, Boye T, Jacobzone C, Begon E, Bernard P, Reguiai Z. [Misdiagnosis of hidradenitis suppurativa continues to be a major issue. The R-ENS Verneuil study]. Ann Dermatol Venereol 2018; 145:331-338. [PMID: 29704958 DOI: 10.1016/j.annder.2018.01.043] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2017] [Revised: 11/20/2017] [Accepted: 01/19/2018] [Indexed: 11/25/2022]
Abstract
OBJECTIVE To provide physicians with an understanding of the factors behind significant delays in the diagnosis of hidradenitis suppurativa (HS) in France. PATIENTS AND METHODS This prospective multicentre national study conducted from October 2015 to March 2016 included all patients consulting for HS. Patient data were collected by means of a standardized questionnaire. Univariate and multivariate analyses were conducted to collect factors associated with a significant time to diagnosis of at least 5.5years, defined as the period between the onset of initial clinical signs and the time of formal diagnosis. RESULTS The 16 participating centres enrolled 312 patients (62% women), of average age 35years. The average age at onset of HS was 22years. Before formal diagnosis by a dermatologist (64% of cases), 170 (54%), 114 (37%) and 45 (15%) patients had previously consulted at least 3, 5 and 10 general physicians, respectively. The average time between the initial clinical signs of HS, the first dermatology visit and the definitive diagnosis was 6.2 and 8.4 years, respectively. Active smoking (OR adjusted 1.85; P=0.027) and disease onset at a younger age (adjusted OR 0.92; P<0.001) were both associated with significant delays in diagnosis. CONCLUSION These results emphasized misdiagnosis among HS patients but did not evidence any association between either sociodemographic or economic characteristics and the existence of significant times to diagnosis.
Collapse
Affiliation(s)
- J Loget
- Service de dermatologie, hôpital Robert-Debré, CHU de Reims, avenue du Général-Koenig, 51092 Reims cedex, France; ResoVerneuil, France.
| | - C Saint-Martin
- Unité d'aide méthodologique, hôpital Robert-Debré, CHU de Reims, avenue du Général-Koenig, 51092 Reims cedex, France
| | - P Guillem
- ResoVerneuil, France; Service de chirurgie adulte, clinique du Val-d'Ouest, 39, chemin de la Vernique, 69130 Ecully, France
| | - L Kanagaratnam
- Unité d'aide méthodologique, hôpital Robert-Debré, CHU de Reims, avenue du Général-Koenig, 51092 Reims cedex, France
| | - P-A Becherel
- ResoVerneuil, France; Service de dermatologie, hôpital privé d'Antony, Ramsay générale de santé, 27, avenue de la Providence, 92160 Antony, France
| | - A Nassif
- ResoVerneuil, France; Service de dermatologie, institut Pasteur, 25-28, rue du Dr-Roux, 75015 Paris, France
| | - A-C Fougerousse
- ResoVerneuil, France; Service de dermatologie, hôpital d'instruction des armées Bégin, 69, avenue de Paris, 94160 Saint-Mandé, France
| | - M Siham
- ResoVerneuil, France; Service de dermatologie, hôpital Avicenne, Assistance publique-Hôpitaux de Paris, 125, rue de Stalingrad, 93000 Bobigny, France
| | - C Girard
- ResoVerneuil, France; Service de dermatologie, centre hospitalier universitaire de Montpellier, 191, avenue du Doyen-Gaston-Giraud, 34295 Montpellier cedex, France
| | - H Barthelemy
- ResoVerneuil, France; Cabinet libéral de dermatologie, 2, rue Soufflot, 89000 Auxerre, France
| | - G Chaby
- ResoVerneuil, France; Service de dermatologie, centre hospitalier universitaire Amiens-Picardie site Nord, place Victor-Pauchet, 80054 Amiens cedex 1, France
| | - G Gabison
- ResoVerneuil, France; Cabinet libéral de dermatologie, 32, avenue du Maréchal-de-Lattre-de-Tassigny, 94410 Saint-Maurice, France
| | - J-L Perrot
- ResoVerneuil, France; Service de dermatologie, hôpital Nord, centre hospitalier universitaire de Saint-Étienne, 42055 Saint-Étienne cedex 2, France
| | - V Pallure
- ResoVerneuil, France; Service de dermatologie, centre hospitalier de Perpignan, 20, avenue du Languedoc, 66000 Perpignan, France
| | - N Beneton
- ResoVerneuil, France; Service de dermatologie, centre hospitalier du Mans, 194, avenue Rubillard, 72037 Le Mans, France
| | - T Boye
- ResoVerneuil, France; Service de dermatologie, hôpital d'instruction des armées Sainte-Anne, 2, boulevard Sainte-Anne, 83000 Toulon, France
| | - C Jacobzone
- ResoVerneuil, France; Service de dermatologie, centre hospitalier de Bretagne Sud, 5, avenue de Choiseul, 56322 Lorient cedex, France
| | - E Begon
- ResoVerneuil, France; Service de dermatologie, hôpital René-Dubos, 6, avenue de l'Île-de-France, 95300 Pontoise, France
| | - P Bernard
- Service de dermatologie, hôpital Robert-Debré, CHU de Reims, avenue du Général-Koenig, 51092 Reims cedex, France
| | - Z Reguiai
- ResoVerneuil, France; Service de dermatologie, polyclinique Courlancy, 38 bis, rue de Courlancy, 51100 Reims, France
| | | |
Collapse
|
31
|
Law Ping Man S, Bouzillé G, Beneton N, Safa G, Dupuy A, Droitcourt C. Drug survival and postdrug survival of first-line immunosuppressive treatments for atopic dermatitis: comparison between methotrexate and cyclosporine. J Eur Acad Dermatol Venereol 2018; 32:1327-1335. [DOI: 10.1111/jdv.14880] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2017] [Accepted: 01/22/2018] [Indexed: 11/25/2022]
Affiliation(s)
- S. Law Ping Man
- University Rennes 1; Rennes France
- Department of Dermatology; CHU Rennes; Rennes France
| | - G. Bouzillé
- INSERM U1099; Rennes France
- University Rennes 1; LTSI; Rennes France
- Clinical Data Center CHU Rennes; Rennes France
- INSERM CIC 1414; Rennes France
| | - N. Beneton
- Department of Dermatology; CH Le Mans; Le Mans France
| | - G. Safa
- Department of Dermatology; CH Saint-Brieuc; Saint-Brieuc France
| | - A. Dupuy
- University Rennes 1; Rennes France
- Department of Dermatology; CHU Rennes; Rennes France
- UPRES EA 7449 REPERES Pharmaco-Epidemiology and Health Services Research; University Rennes 1 and French School of Public Health; Rennes France
| | - C. Droitcourt
- University Rennes 1; Rennes France
- Department of Dermatology; CHU Rennes; Rennes France
- INSERM CIC 1414; Rennes France
- UPRES EA 7449 REPERES Pharmaco-Epidemiology and Health Services Research; University Rennes 1 and French School of Public Health; Rennes France
| |
Collapse
|
32
|
Allal S, Guillem P, Fougerousse A, Beneton N, Maccari F, Labeille B, Tisseran E, Vuering F, Vergote-Pelamourgues S, Cinotti E, Perrot JL. Données démographiques et biométriques de 882 sujets atteints de maladie de Verneuil : EpiVer étude multicentrique française ville-hôpital. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.325] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
33
|
Mahé E, Tubach F, Jullien D, Paul C, Beylot-Barry M, Dupuy A, Viguier M, Beneton N, Richard MA, Sbidian E, Joly P, Chosidow O, Bachelez H. Association entre âge de début du psoriasis et statut social, éducatif et professionnel à l’âge adulte. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.137] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
34
|
Tetu P, Mangana J, Dummer R, Dutriaux C, Beneton N, Dalle S, Meyer N, Oriano B, Delyon J, Michielin O, Lebbe C. Efficacité de la combithérapie par nivolumab et ipilimumab dans les mélanomes métastatiques. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
35
|
Samimi M, Durieux-Verde M, Caille A, Mazereeuw-Hautier J, Boccara O, Martin L, Chiaverini C, Eschard C, Beneton N, Vabres P, Balguerie X, Plantin P, Bessis D, Barbarot S, Dadban A, Droitcourt C, Leducq S, Lorette G, Morel B, Maruani A. Clinical and haemodynamic risk factors associated with discrepancies in lower limb length with capillary malformations: data from the national paediatric French cohort CONAPE. Br J Dermatol 2017; 178:520-526. [PMID: 28963775 DOI: 10.1111/bjd.16017] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/20/2017] [Indexed: 01/19/2023]
Abstract
BACKGROUND Genetics discoveries have allowed for a better understanding of capillary malformations (CMs) associated with overgrowth syndrome. However, molecular analyses are still not easy to perform or interpret. Other analytical methods are needed. OBJECTIVES To identify clinical and haemodynamic factors associated with leg length discrepancy (LLD) in children with CMs of the lower limbs. METHODS Data were obtained from the multicentre French national cohort CONAPE (COhorte Nationale d'enfants atteints d'Angiome Plan de membrE inférieur), from children aged 2-12 years old with CMs of the lower limbs. Clinical characteristics were prospectively collected. Haemodynamic factors were measured by an sonographer who calculated the arterial blood flow (ABF) in both lower limbs. An ABF difference ≥ 50% between the two lower limbs was considered relevant. LLD ≥ 2% was determined by the same radiologist on centralized radiographs. RESULTS We analysed data at baseline for 96 children. The mean ± SD age was 5·6 ± 3·1 years; 49 (51%) were male; and 14 (15%) showed LLD. In total, 32 patients (33%) had venous anomalies, 13 (14%) lymphatic anomalies and in one child a diagnosis of Parkes Weber syndrome was made. Only an increased circumference above the knee was more frequent with than without LLD (43% vs. 13%, P = 0·02). In all, 10/79 patients (13%) showed a difference in ABF ≥ 50%: four had LLD. The frequency of differences in ABF ≥ 50% was greater with than without LLD [33% (n = 4/12) vs. 9% (n = 6/67), P = 0·04]. CONCLUSIONS ABF measured by Duplex ultrasonography is a simple, low-cost and noninvasive complementary examination for help in detecting LLD, with a difference of ≥ 50% possibly associated.
Collapse
Affiliation(s)
- M Samimi
- University François Rabelais Tours, 37000, Tours, France.,Department of Dermatology, CHRU Tours, 37044, Tours Cedex 9, France
| | - M Durieux-Verde
- Department of Dermatology, CHRU Tours, 37044, Tours Cedex 9, France
| | - A Caille
- University François Rabelais Tours, 37000, Tours, France.,CHRU Tours, Clinical Investigation Center-INSERM 1415, INSERM U1246, SPHERE, 37000, Tours, France
| | - J Mazereeuw-Hautier
- Department of Dermatology, University Hospital Center of Toulouse, 31000, Toulouse, France
| | - O Boccara
- Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), University Hospital Necker-Enfants Malades, 75015, Paris, France
| | - L Martin
- Department of Dermatology, University Hospital Center of Angers, 49000, Angers, France
| | - C Chiaverini
- Department of Dermatology, University Hospital Center of Nice, 06000, Nice, France
| | - C Eschard
- Department of Dermatology, University Hospital Center of Reims, 51100, Reims, France
| | - N Beneton
- Department of Dermatology, Hospital Center of le Mans, 72000, le Mans, France
| | - P Vabres
- Department of Dermatology, University Hospital Center of Dijon, 21000, Dijon, France
| | - X Balguerie
- Department of Dermatology, University Hospital Center of Rouen, 76000, Rouen, France
| | - P Plantin
- Department of Dermatology, Hospital Center of Quimper, 29000, Quimper, France
| | - D Bessis
- Department of Dermatology, University Hospital Center of Montpellier, 34000, Montpellier, France
| | - S Barbarot
- Department of Dermatology, University Hospital Center of Nantes, 44000, Nantes, France
| | - A Dadban
- Department of Dermatology, University Hospital Center of Amiens, 80000, Amiens, France
| | - C Droitcourt
- Department of Dermatology, University Hospital Center of Rennes, 35000, Rennes, France
| | - S Leducq
- University François Rabelais Tours, 37000, Tours, France.,Department of Dermatology, CHRU Tours, 37044, Tours Cedex 9, France
| | - G Lorette
- University François Rabelais Tours, 37000, Tours, France.,Department of Dermatology, CHRU Tours, 37044, Tours Cedex 9, France
| | - B Morel
- University François Rabelais Tours, 37000, Tours, France.,Department of Paediatric Radiology, CHRU Tours, 37044, Tours Cedex 9, France
| | - A Maruani
- University François Rabelais Tours, 37000, Tours, France.,Department of Dermatology, CHRU Tours, 37044, Tours Cedex 9, France.,CHRU Tours, Clinical Investigation Center-INSERM 1415, INSERM U1246, SPHERE, 37000, Tours, France
| | | |
Collapse
|
36
|
Mahé E, Maccari F, Beauchet A, Quiles-Tsimaratos N, Beneton N, Parier J, Barthelemy H, Goujon-Henry C, Chaby G, Thomas-Beaulieu D, Géner G, Wagner L, Pallure V, Devaux S, Vermersch-Langlin A, Pfister P, Jégou J, Livideanu C, Sigal ML. Patients atteints de psoriasis : analyse de la population insatisfaite de sa prise en charge. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.03.025] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
37
|
Sbidian E, Giboin C, Bachelez H, Paul C, Beylot-Barry M, Dupuy A, Viguier M, Lacour JP, Schmutz JL, Bravard P, Mahé E, Beneton N, Misery L, Delaporte E, Modiano P, Barbarot S, Regnier E, Jullien D, Richard MA, Joly P, Tubach F, Chosidow O. Factors associated with the choice of the first biologic in psoriasis: real-life analysis from the Psobioteq cohort. J Eur Acad Dermatol Venereol 2017; 31:2046-2054. [PMID: 28609574 DOI: 10.1111/jdv.14406] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2017] [Accepted: 05/18/2017] [Indexed: 12/29/2022]
Abstract
BACKGROUND Decision-making is a complex process. The aim of our study was to assess factors associated with the choice of the first biological treatment in patients with moderate-to-severe psoriasis. METHODS Data on all patients included in the French prospective, observational, cohort, Psobioteq and initiating a first biologic prescription between July 2012 and July 2016 were analysed. Demographic information and clinical features were collected during routine clinical assessments by the dermatology team at the recruiting centres using a standardized case report form. The primary outcome was the nature of the first biologic treatment. Four groups were identified as follows: adalimumab, etanercept, ustekinumab and infliximab groups. Factors associated with the choice of the first biological agent were determined by a multinomial logistic regression model adjusted on year of inclusion. RESULTS The study population included the 830 biological-naïve patients who initiated a first biological agent. The mean age was 46.6 years (±SD 13.9), and 318 patients (38.3%) were female. The most commonly prescribed biologic was adalimumab: 355 (42.8%) patients, then etanercept (n = 247, 29.8%), ustekinumab (n = 194, 23.4%) and infliximab (n = 34, 4.0%). In the multinomial logistic regression analysis, patients were significantly more likely to receive adalimumab if they had a severe psoriasis as defined by baseline PASI or if they had psoriatic arthritis compared to etanercept (aOR, 0.42; 95% CI, 0.16-1.07) and ustekinumab (aOR, 0.15; 95% CI, 0.04-0.52). Patients were significantly more likely to receive ustekinumab (aOR, 2.39; 95% CI, 1.04-5.50) if they had a positive screening for latent tuberculosis compared to adalimumab. Younger patients were also more likely to receive ustekinumab. Patients with chronic obstructive pulmonary disease were more likely to be prescribed ustekinumab or etanercept compared to adalimumab. There was a trend in favour of etanercept prescription in patients with cardiovascular comorbidities, metabolic syndrome and in patients with a history of cancer. CONCLUSION We identified patient- and disease-related factors that have important influence on the choice of the first biological agent in clinical practice. Clinicians appear to have a holistic approach to patient characteristics when choosing a biological agent in psoriasis.
Collapse
Affiliation(s)
- E Sbidian
- Département de Dermatologie, AP-HP, Hôpitaux Universitaires Henri Mondor, UPEC, Créteil, France.,INSERM, Centre d'Investigation Clinique 1430, Créteil, France.,EA 7379 EpidermE, Université Paris-Est Créteil (UPEC), Créteil, France
| | - C Giboin
- Département Biostatistique, Santé Publique et Information Médicale, Centre de Pharmaco-épidémiologie, CIC 1421, AP-HP, Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, Paris, France
| | - H Bachelez
- Service de Dermatologie, Institut Imagine, AP-HP Hôpital Saint-Louis, INSERM UMR 1163, SorbonneParis Cité Université Paris Diderot, Paris, France
| | - C Paul
- Département de Dermatologie, Hôpitaux Universitaires de Toulouse, UMR INSERM 1056, Université Paul Sabatier, Toulouse, France
| | - M Beylot-Barry
- Département de Dermatologie, INSERM U1053, Hôpital Saint-André, Université de Bordeaux, Bordeaux, France
| | - A Dupuy
- Département de Dermatologie, INSERM CIC 1414, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, Université de Rennes 1, Rennes, France
| | - M Viguier
- Département de Dermatologie, Hôpitaux Universitaires Robert Debré, Reims, France
| | - J-P Lacour
- Département de Dermatologie, Centre de Référence Maladies Rares, Hôpital l'Archet 2, Centre Hospitalier Universitaire de Nice, Nice, France
| | - J-L Schmutz
- Département de Dermatologie et Allergologie, Hôpitaux de Brabois, Centre Hospitalier Régional Universitaire de Nancy, Nancy, France
| | - P Bravard
- Département de Dermatologie, Groupe Hospitalier du Havre, Le Havre, France
| | - E Mahé
- Département de Dermatologie, Hôpital Victor Dupouy, Argenteuil, France
| | - N Beneton
- Département de Dermatologie, Centre Hospitalier du Mans, Le Mans, France
| | - L Misery
- Département de Dermatologie, Centre Hospitalier Régional Universitaire de Brest, Brest, France
| | - E Delaporte
- Département de Dermatologie, Centre Hospitalier Régional Universitaire de Lille, Lille, France
| | - P Modiano
- Département de Dermatologie, Groupement des Hôpitaux de l'Institut Catholique de Lille, Hôpital Saint-Vincent-de-Paul, Lille, France
| | - S Barbarot
- Département de Dermatologie, Centre Hospitalier Universitaire de Nantes, Nantes, France
| | - E Regnier
- Département de Dermatologie, AP-HP, Hôpitaux Universitaires Cochin, Université Paris Descartes Paris V, Paris, France
| | - D Jullien
- Département de Dermatologie, HCL, Centre Hospitalier Universitaire, Hôpital Edouard Herriot, Lyon, France
| | - M-A Richard
- Département de Dermatologie, Centre Hospitalier Universitaire, Hôpital La Timone, Marseille, France
| | - P Joly
- Department of Dermatology, Rouen University Hospital, INSERM U 1234, Normandie University, Rouen, France
| | - F Tubach
- Département Biostatistique, Santé Publique et Information Médicale, Centre de Pharmaco-épidémiologie, CIC 1421, AP-HP, Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, Paris, France.,Université Pierre et Marie Curie, Sorbonne Universités, Paris, France.,UMR 1123, CIC 1421, ECEVE, INSERM, Paris, France
| | - O Chosidow
- Département de Dermatologie, AP-HP, Hôpitaux Universitaires Henri Mondor, UPEC, Créteil, France.,INSERM, Centre d'Investigation Clinique 1430, Créteil, France.,EA 7379 EpidermE, Université Paris-Est Créteil (UPEC), Créteil, France
| |
Collapse
|
38
|
Guinard E, Bulai Livideanu C, Barthélémy H, Viguier M, Reguiai Z, Richard M, Jullien D, Beneton N, Bara C, Vabres P, Grandvuillemin A, Marguery M, Amelot F, Konstantinou M, Bagheri H, Paul C. Active tuberculosis in psoriasis patients treated with TNF antagonists: a French nationwide retrospective study. J Eur Acad Dermatol Venereol 2016; 30:1336-41. [DOI: 10.1111/jdv.13633] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2016] [Accepted: 01/20/2016] [Indexed: 12/17/2022]
Affiliation(s)
- E. Guinard
- Service de dermatologie; CHU Toulouse Larrey; Université Paul Sabatier; Toulouse France
| | - C. Bulai Livideanu
- Service de dermatologie; CHU Toulouse Larrey; Université Paul Sabatier; Toulouse France
| | | | - M. Viguier
- Service de dermatologie; CHU Saint Louis; Paris France
| | - Z. Reguiai
- Service de dermatologie; CHU de Reims; Reims France
| | - M.A. Richard
- Service de dermatologie; Hôpital Timone; Assistance publique des Hôpitaux de Marseille; Université Aix Marseille; Marseille France
- UMR 911; INSERM CRO2, “Centre de recherche en oncologie biologique et onco phamacologie; Marseille France
| | - D. Jullien
- Service de dermatologie; CHU Lyon; Université de Lyon; Lyon France
| | - N. Beneton
- Service de dermatologie; CH du Mans; Le Mans France
| | - C. Bara
- Service de dermatologie; CH du Mans; Le Mans France
| | - P. Vabres
- Service de dermatologie; CHU Dijon; Dijon France
| | | | - M.C. Marguery
- Service de dermatologie; CHU Toulouse Larrey; Université Paul Sabatier; Toulouse France
| | - F. Amelot
- Service de dermatologie; CHU Toulouse Larrey; Université Paul Sabatier; Toulouse France
| | - M.P. Konstantinou
- Service de dermatologie; CHU Toulouse Larrey; Université Paul Sabatier; Toulouse France
| | - H. Bagheri
- Service de pharmacologie médicale et clinique; CHU Toulouse; Toulouse France
| | - C. Paul
- Service de dermatologie; CHU Toulouse Larrey; Université Paul Sabatier; Toulouse France
| | | |
Collapse
|
39
|
Samimi M, Molet L, Fleury M, Laude H, Carlotti A, Gardair C, Baudin M, Gouguet L, Maubec E, Avenel-Audran M, Esteve E, Wierzbicka-Hainaut E, Beneton N, Aubin F, Rozenberg F, Dupin N, Avril MF, Lorette G, Guyetant S, Coursaget P, Touzé A. Prognostic value of antibodies to Merkel cell polyomavirus T antigens and VP1 protein in patients with Merkel cell carcinoma. Br J Dermatol 2016; 174:813-22. [PMID: 26600395 DOI: 10.1111/bjd.14313] [Citation(s) in RCA: 51] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/16/2015] [Indexed: 02/01/2023]
Abstract
BACKGROUND Merkel cell polyomavirus (MCPyV) is the main aetiological agent of Merkel cell carcinoma (MCC). Serum antibodies against the major MCPyV capsid protein (VP1) are detected in the general population, whereas antibodies against MCPyV oncoproteins (T antigens) have been reported specifically in patients with MCC. OBJECTIVES The primary aim was to assess whether detection of serum antibodies against MCPyV proteins at baseline was associated with disease outcome in patients with MCC. The secondary aim was to establish whether evolution of these antibodies during follow-up was associated with the course of the disease. METHODS Serum T-antigen and VP1 antibodies were assessed by enzyme-linked immunosorbent assay using recombinant proteins in a cohort of 143 patients with MCC, including 84 patients with serum samples available at baseline. RESULTS Low titres of VP1 antibodies at baseline (< 10 000) were significantly and independently associated with increased risk of recurrence [hazard ratio (HR) 2·71, 95% confidence interval (CI) 1·13-6·53, P = 0·026] and death (HR 3·74, 95% CI 1·53-9·18, P = 0·004), whereas T-antigen antibodies were not found to be associated with outcome. VP1 antibodies did not differ between patients in remission and those with recurrence or progression during follow-up. However, T-antigen antibodies were more frequently detected in patients with recurrence or progression at 12 months (P = 0·020) and 24 months (P = 0·016) after diagnosis. CONCLUSIONS VP1 antibodies constitute a prognostic marker at baseline, whereas T-antigen antibodies constitute a marker of disease recurrence or progression if detected > 12 months after diagnosis.
Collapse
Affiliation(s)
- M Samimi
- Université François Rabelais, Tours, France.,INRA, UMR 1282 ISP, 31 Avenue Monge, 37200, Tours, France.,Dermatology Department, CHU Tours, Avenue de la République, 37170, Tours, France
| | - L Molet
- Assistance Publique des Hôpitaux de Paris, Virology, Pathology and Dermatology Departments, Hôpital Cochin, 27 Rue du Fbg Saint-Jacques, 75679, Paris CEDEX 14, France.,Institut Cochin, Inserm U1016, Université Paris Descartes, 22 Rue Méchain, 75014, Paris, France
| | - M Fleury
- Université François Rabelais, Tours, France.,INRA, UMR 1282 ISP, 31 Avenue Monge, 37200, Tours, France.,LUNAM Université, Groupe d'Etude des Interactions Hôte-Pathogéne, UPRES EA 3142, Angers, France
| | - H Laude
- Assistance Publique des Hôpitaux de Paris, Virology, Pathology and Dermatology Departments, Hôpital Cochin, 27 Rue du Fbg Saint-Jacques, 75679, Paris CEDEX 14, France.,Institut Cochin, Inserm U1016, Université Paris Descartes, 22 Rue Méchain, 75014, Paris, France
| | - A Carlotti
- Assistance Publique des Hôpitaux de Paris, Virology, Pathology and Dermatology Departments, Hôpital Cochin, 27 Rue du Fbg Saint-Jacques, 75679, Paris CEDEX 14, France
| | - C Gardair
- Université François Rabelais, Tours, France.,Pathology Department, CHU Tours, Avenue de la République, 37170, Tours, France
| | - M Baudin
- Université François Rabelais, Tours, France.,INRA, UMR 1282 ISP, 31 Avenue Monge, 37200, Tours, France
| | - L Gouguet
- Université François Rabelais, Tours, France.,INRA, UMR 1282 ISP, 31 Avenue Monge, 37200, Tours, France
| | - E Maubec
- Assistance Publique des Hôpitaux de Paris, Dermatology Department, Hôpital Bichat, 46 Rue Henri Huchard, 75877, Paris CEDEX 18, France.,Assistance Publique des Hôpitaux de Paris, Dermatology Department, Hôpital Avicenne, 125, rue de Stalingrad, 93009, Bobigny, France
| | - M Avenel-Audran
- LUNAM Université, CHU Angers, Dermatology Department, 4 Rue Larrey, 49933, Angers, France
| | - E Esteve
- CHR Orléans, Dermatology Department, 14 Avenue de l'Hôpital, 45067, Orléans CEDEX 2, France
| | - E Wierzbicka-Hainaut
- CHU Poitiers, Dermatology Department, 2 Rue de la Milétrie, 86021, Poitiers CEDEX, France
| | - N Beneton
- CHR Le Mans, Dermatology Department, 194 Avenue Rubillard, 72037, Le Mans CEDEX 09, France
| | - F Aubin
- Université de Franche Comté, EA3181, SFR 4234, CHU Besançon, Dermatology Department, 2 Boulevard Fleming, 25030, Besançon, France
| | - F Rozenberg
- Assistance Publique des Hôpitaux de Paris, Virology, Pathology and Dermatology Departments, Hôpital Cochin, 27 Rue du Fbg Saint-Jacques, 75679, Paris CEDEX 14, France.,Institut Cochin, Inserm U1016, Université Paris Descartes, 22 Rue Méchain, 75014, Paris, France
| | - N Dupin
- Assistance Publique des Hôpitaux de Paris, Virology, Pathology and Dermatology Departments, Hôpital Cochin, 27 Rue du Fbg Saint-Jacques, 75679, Paris CEDEX 14, France.,Institut Cochin, Inserm U1016, Université Paris Descartes, 22 Rue Méchain, 75014, Paris, France
| | - M F Avril
- Assistance Publique des Hôpitaux de Paris, Virology, Pathology and Dermatology Departments, Hôpital Cochin, 27 Rue du Fbg Saint-Jacques, 75679, Paris CEDEX 14, France.,Institut Cochin, Inserm U1016, Université Paris Descartes, 22 Rue Méchain, 75014, Paris, France
| | - G Lorette
- Université François Rabelais, Tours, France.,INRA, UMR 1282 ISP, 31 Avenue Monge, 37200, Tours, France.,Dermatology Department, CHU Tours, Avenue de la République, 37170, Tours, France
| | - S Guyetant
- Université François Rabelais, Tours, France.,Pathology Department, CHU Tours, Avenue de la République, 37170, Tours, France
| | - P Coursaget
- Université François Rabelais, Tours, France.,INRA, UMR 1282 ISP, 31 Avenue Monge, 37200, Tours, France
| | - A Touzé
- Université François Rabelais, Tours, France.,INRA, UMR 1282 ISP, 31 Avenue Monge, 37200, Tours, France
| |
Collapse
|
40
|
Khemis A, Maccari F, Fougerousse AC, Mahé E, Begon E, Beneton N, Boyé T, Reguiai Z. Enquête multicentrique évaluant l’utilisation du METHOtrexate en PRAtique Courante en traitement du psoriasis : étude METHOPRAC. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
41
|
Joly P, Houivet E, Prost C, Maho-Vaillant M, Picard Dahan C, Duvert Lehembre S, Labeille B, Richard M, Bernard P, Dupuy A, Bouaziz J, Oro S, Chosidow O, Vabres P, Delaporte E, Avenel M, Alexandre M, Caux F, Incan M, Bedane C, Quereux G, Machet L, Dereure O, Skowron F, Franck N, Beylot-Barry M, Doutre M, Beneton N, Debarbieux S, Jullien D, Misery L, Ferranti V, Benichou J, Musette P. Étude randomisée évaluant l’efficacité et la tolérance du rituximab associé à une corticothérapie allégée par rapport à une corticothérapie standard dans le traitement du pemphigus. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
42
|
Samimi M, Molet L, Fleury M, Laude H, Carlotti A, Gardair C, Baudin M, Gouguet L, Maubec E, Avenel-Audran M, Esteve E, Wierzbiecka Hainault E, Beneton N, Aubin F, Rozenberg F, Dupin N, Avril MF, Lorette G, Guyetant S, Coursaget P, Touze A. Valeur pronostique des anticorps anti-VP1 et anti-T du MCPyV dans une cohorte de patients avec carcinome de Merkel. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
43
|
Finon A, Maillard H, Bens G, Berton M, Dannepond C, Lagier L, Le Bidre E, Beneton N, Machet L. Le ratio neutrophiles/lymphocytes mesuré avant l’instauration d’un inhibiteur de BRAF pour un mélanome métastatique n’est pas associé à la survie globale des patients. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.509] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
44
|
Guinard E, Bulai Livideanu C, Barthélémy H, Viguier M, Reguiai Z, Richard MA, Jullien D, Martinelli J, Beneton N, Bara C, Vabres P, Grandvuillemin A, Marguery M, Amelot F, Ofaiche J, Konstantinou MP, Bagheri H, Paul C. Tuberculose active et psoriasis traité par anti-TNF alpha : étude nationale. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.522] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
45
|
Zaragoza J, Caille A, Beneton N, Bens G, Christiann F, Maillard H, Machet L. High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma. Br J Dermatol 2015; 174:146-51. [PMID: 26343230 DOI: 10.1111/bjd.14155] [Citation(s) in RCA: 117] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/23/2015] [Indexed: 01/04/2023]
Abstract
BACKGROUND There is an unmet need to identify markers predictive of response to ipilimumab in patients with melanoma because the number of responders to ipilimumab is low and its cost is very high. An increase in absolute lymphocyte count (ALC) or low neutrophil/lymphocyte ratio (NLR) just before the third infusion has been reported to be associated with better overall survival (OS). OBJECTIVES Our aim was to determine whether NLR measured before the first infusion was associated with OS. PATIENTS AND METHODS Data were collected on a consecutive series of 58 patients treated with ipilimumab in four hospitals, including 51 at stage M1c and four at stage M1b. The influences of the NLR and other factors such as lactate dehydrogenase (LDH), performance status, ALC, absolute neutrophil count (ANC) and corticosteroids on survival were studied. We also assessed this association with NLR categorized as a binary variable. The cut-off value for the NLR was determined with time-dependent receiver operating characteristic (ROC) analysis. Univariate and multivariate analyses were performed using Cox regression models. RESULTS High NLR (≥) 4, high ANC LDH levels (>2), performance status ≥2, symptomatic brain metastases, and corticosteroids before week 1 were associated with poorer survival on univariate analysis. Using multivariate analysis, a significant association between high NLR (continuous variable) and poorer survival was demonstrated and remained significant after adjustment on potential confounders [hazard ratio (HR) = 1·21, 95% confidence interval (CI) 1·07-1·36]. NLR ≥4 was an independent prognostic factor (HR = 2·2, 95% CI 1·01-4·78). Intake of corticosteroids before week 1 was not an independent prognostic factor (HR = 1·28, 95% CI 0·54-3·06). CONCLUSIONS High NLR (≥4) before initiating ipilimumab treatment in patients with metastatic melanoma is an independent prognostic indicator of poor survival.
Collapse
Affiliation(s)
- J Zaragoza
- Department of Dermatology, Centre Hospitalier Régional et Universitaire (CHRU) de Tours, Tours, 37044, France
| | - A Caille
- Inserm Centre d'Investigation Clinique (CIC) 1415, Centre Hospitalier Régional et Universitaire (CHRU) de Tours, Tours, 37044, France.,PRES Centre, Val de Loire University, at University François Rabelais de Tours, Tours, France
| | - N Beneton
- Department of Dermatology, Centre Hospitalier (CH), Le Mans, France
| | - G Bens
- Department of Dermatology, Centre Hospitalier Régional (CHR), d'Orléans, France
| | | | - H Maillard
- Department of Dermatology, Centre Hospitalier (CH), Le Mans, France
| | - L Machet
- Department of Dermatology, Centre Hospitalier Régional et Universitaire (CHRU) de Tours, Tours, 37044, France.,PRES Centre, Val de Loire University, at University François Rabelais de Tours, Tours, France.,Inserm U 930, University Francois Rabelais, Tours, France
| |
Collapse
|
46
|
Lagier L, Mazereeuw-Hautier J, Raffin D, Beneton N, Lorette G, Maruani A. Les dermites du siège du nourrisson. Réponses au pré-test. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2014.10.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
47
|
Lagier L, Mazereeuw-Hautier J, Raffin D, Beneton N, Lorette G, Maruani A. Les dermites du siège du nourrisson. Ann Dermatol Venereol 2015; 142:54-61; quiz 53, 62. [DOI: 10.1016/j.annder.2014.09.611] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2014] [Revised: 09/18/2014] [Accepted: 09/25/2014] [Indexed: 01/05/2023]
|
48
|
Lagier L, Mazereeuw-Hautier J, Raffin D, Beneton N, Lorette G, Maruani A. Les dermites du siège du nourrisson. Pré-test. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2014.10.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
49
|
Phan C, Sigal ML, Estève E, Reguiai Z, Barthélémy H, Beneton N, Maccari F, Lahfa M, Thomas-Beaulieu D, Le Guyadec T, Vermersch-Langlin A, Mery-Bossard L, Pallure V, Kemula M, Labeille B, Beauchet A, Mahé E. Psoriasis in the elderly: epidemiological and clinical aspects, and evaluation of patients with very late onset psoriasis. J Eur Acad Dermatol Venereol 2014; 30:78-82. [DOI: 10.1111/jdv.12850] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2014] [Accepted: 10/14/2014] [Indexed: 01/08/2023]
Affiliation(s)
- C. Phan
- Department of Dermatology; Hôpital Victor Dupouy Hospital; Argenteuil France
| | - M.-L. Sigal
- Department of Dermatology; Hôpital Victor Dupouy Hospital; Argenteuil France
| | - E. Estève
- Department of Dermatology; Centre Hospitalier Régional d'Orléans; Orléans France
| | - Z. Reguiai
- Department of Dermatology; Hôpital Robert Debré; Reims France
| | - H. Barthélémy
- Department of Dermatology; Centre Hospitalier d'Auxerre; Auxerre France
| | - N. Beneton
- Department of Dermatology; Centre Hospitalier du Mans; Le Mans France
| | - F. Maccari
- Department of Dermatology; Hôpital d'Instruction des Armées Bégin; Saint-Mandé France
| | - M. Lahfa
- Department of Dermatology; Hôpital Larrey, Centre Hospitalier Universitaire de Toulouse; Paul Sabatier-Toulouse 3 University; Toulouse France
| | - D. Thomas-Beaulieu
- Department of Dermatology; Centre Hospitalier de Poissy; Saint Germain en Laye France
| | - T. Le Guyadec
- Department of Dermatology; Hôpital d'Instruction des Armées Percy; Clamart France
| | | | - L. Mery-Bossard
- Department of Dermatology; Hôpital François Quesnay; Mantes La Jolie France
| | - V. Pallure
- Department of Dermatology; Centre Hospitalier Universitaire Saint-Eloi; Montpellier France
| | - M. Kemula
- Private Office; Charenton-Le Pont France
| | - B. Labeille
- Department of Dermatology; Centre Hospitalier Universitaire; Saint-Etienne France
| | - A. Beauchet
- Department of Public Health; Centre Hospitalier Universitaire Ambroise Paré; Assistance Publique-Hôpitaux de Paris; Boulogne Billancourt France
| | - E. Mahé
- Department of Dermatology; Hôpital Victor Dupouy Hospital; Argenteuil France
| | | |
Collapse
|
50
|
Martignac B, Gagnadoux F, Trzepizur W, Beneton N, Vinchon F, Paris A, Montani D, Goupil F. Atteinte pulmonaire sévère au cours de la neurofibromatose de type 1. Rev Mal Respir 2014; 31:621-3. [DOI: 10.1016/j.rmr.2013.10.643] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2013] [Accepted: 10/03/2013] [Indexed: 11/27/2022]
|